CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

NCT ID: NCT06355739

Last Updated: 2024-04-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-01
• Study Completion Date: 2027-01-15

Brief Summary

To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children

Conditions

B Lymphocytic Leukemia; B Lymphoblastic Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CD19 autotransfusion for B-cell acute lymphoblastic leukemia in children

Group Type: OTHER

CAR T cell injection

Intervention Type: DEVICE

intravenous injection

Interventions

CAR T cell injection

intravenous injection

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1, age 3-18 years old (including boundary value), male and female;

2. The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoblastic

Patients with tumors who meet one of the following conditions:

• Complete marrow response (MRD>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy

Complete response at the molecular level and immunology (characterized by specific molecular markers and immunophenotypes prior to treatment)

Patients, did not turn negative after treatment);

• Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥

12 months) and did not achieve complete remission after 1 course of standard induction regimen (MRD>1%);

• Recurrence after bone marrow transplantation;
• Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined

recrudescence

3. Lansky score ≥60;

4, the treatment related antigen test result is positive (CD19/CD20/CD22);

5. The expected survival period from the signing date of the informed consent is more than 3 months;

6, HGB≥70g/L (blood transfusion);

7, liver and kidney function, cardiopulmonary function meet the following requirements:

1. Creatinine ≤1.5×ULN;

2. Left ventricular ejection fraction ≥50%;

3. Blood oxygen saturation >90%;

4. Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-

Exclusion Criteria

• 1, severe cardiac insufficiency, left ventricular ejection fraction <50%;

2, have a history of severe lung function impairment;

3. Combined with other advanced malignant tumors;

4, combined with serious infection and can not be effectively controlled;

5, combined with serious autoimmune disease or congenital immune deficiency;

6, active hepatitis (hepatitis B virus deoxyribonucleic acid [HBVDNA] or hepatitis C virus ribonucleic acid [HCVRNA] positive);

7, human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection;

8. Have a history of severe allergy to biological products (including antibiotics);

9. Patients with allogeneic hematopoietic stem cell transplantation still had acute graft-versus-host response (GvHD) one month after immunosuppressant discontinuation;

10, the presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, as well as patients deemed unsuitable for participation in the study by the investigator.

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhu Xiaofan

OTHER

Sponsor Role: lead

Responsible Party

Zhu Xiaofan

Head of department

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China

Site Status: RECRUITING

InstituteHBDH

Tianjin, Tianjin Municipality, China

Site Status: NOT_YET_RECRUITING

Countries

China

Facility Contacts

Xiaofan Zhu, MD

Role: primary

xfzhu@ihcams.ac.cn

86-21-23909001

Zhu Xiaofan

Role: primary

xfzhu@ihcams.ac.cn

86-21-23909001

Other Identifiers

BIC-19GG, BIC-2019,BIC-2219

Identifier Type: -

Identifier Source: org_study_id